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ABSTRACT
Objective To assess the efficacy and safety of varenicline
(a licensed cigarette smoking cessation aid) in helping
users of smokeless tobacco to quit.
Design Double blind, placebo controlled, parallel group,
multicentre, randomised controlled trial.
Setting Medical clinics (mostly primary care) in Norway
and Sweden.
Participants Men and women aged ≥18 who used
smokeless tobacco at least eight times a day, with no
abstinence period over three months within one year
before screening, who wanted to quit all tobacco use.
Participants were excluded if they used any other form of
tobacco (except smokeless tobacco) or medication to
stopsmokingwithinthreemonthsofscreeningorhadany
pre-existing medical or psychiatric condition.
InterventionsVarenicline1mgtwicedaily(titratedduring
the first week) or placebo for 12 weeks, with 14 weeks’
follow-up after treatment.
Main outcome measures The primary end point was the
four week continuous abstinence rate at the end of
treatment (weeks 9-12) confirmed with cotinine
concentration. A secondary end point was continuous
abstinence rate for weeks 9-26. Safety and tolerability
were also evaluated.
Results 431 participants (213 varenicline; 218 placebo)
were randomised and received at least one dose of study
drug. Participants’ demographics and baseline use of
smokeless tobacco were similar (89% (189) and 90%
(196), respectively, were men; mean age in both groups
was 43.9; participants used smokelesstobacco products
about 15 times a day, and about 80% first used
smokeless tobacco within 30 minutes after awakening).
Continuous abstinence rate at week 9-12 was higher in
the varenicline group than the placebo group (59% (125)
v 39% (85); relative risk 1.60, 95% confidence interval
1.32 to 1.87, P<0.001; risk difference 20%; number
needed to treat 5). The advantage of varenicline over
placebo persisted through 14 weeks of follow-up
(continuousabstinencerateat week9-26was 45%(95)v
34% (73); relative risk 1.42, 1.08 to 1.79, P=0.012; risk
difference 11%; number needed to treat 9). The most
common adverse events in the varenicline group
comparedwiththeplacebogroupwerenausea(35%(74)
v 6% (14)), fatigue (10% (22) v 7% (15)), headache (10%
(22) v 9% (20)), and sleep disorder (10% (22) v 7% (15)).
Few adverse events led to discontinuation of treatment
(9% (19) and 4% (9), respectively), and serious adverse
events occurred in two (1%) and three (1%) participants,
respectively.
Conclusion Varenicline can help people to give up
smokeless tobacco and has an acceptable safety profile.
The response rate in the placebo group in this study was
high, suggesting a population less resistant to treatment
than smokers.
Trial Registration NCT00717093.
INTRODUCTION
The use of smokeless tobacco products is increasingin
many countries. In Scandinavia the use of smokeless
tobacco, specifically snus (a moist tobacco product,
consumed by placing it under the upper lip), is well
established. In Swedish men the prevalence of use is
higher than that of smoking (19% v 11% in 2008),
12
and in Norway a considerable proportion (32%) of
young men (aged 16-35) use snus every day.
3 Despite
the high prevalence of use of smokeless tobacco in
Scandinavia, the largest market in Western countries
is in the United States, where about 5% of adult men
and 13% of male adolescents are daily users of smoke-
less tobacco, and the trend is increasing.
4-6
Smokeless tobacco is often considered less harmful
thansmoking,
7andthiscouldexplainwhyinSwedenit
is used by nearly 30% of male smokers trying to quit.
8
According to the American Cancer Society, however,
up to half of users of smokeless tobacco would like to
quit in the next year.
9 While there are several hundred
studies on smoking cessation that have documented
the efficacy of pharmacotherapy and behavioural sup-
port, there are far fewer studies on cessation of smoke-
less tobacco, perhaps because of the widely held belief
that it is less harmful than smoking. Most of the pub-
lished studies have evaluated brief behavioural meth-
ods. In a Cochrane meta-analysis of 12 studies from
2007, behavioural interventions were found to be
effective.
10 In contrast, pharmacological treatments
have not proved effective. In an analysis of eight trials
of pharmacological treatment, the 2007 Cochrane
review found that pharmacotherapy had no effect:
two trials used bupropion (odds ratio 0.86, 95%
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used nicotine gum (0.98, 0.59 to 1.63), and four trials
used nicotine patches (1.16, 0.88 to 1.54).
10 A more
recent randomised placebo controlled trial showed a
non-significanttrendtowardsefficacywitha4mgnico-
tine lozenge (1.5, 0.7 to 2.1).
11
Varenicline is a specific partial agonist of the α4β2
nicotinic acetylcholine receptor,
12 which is effective in
increasingabstinenceratesamongcigarettesmokers.
13
Varenicline could be expected to help users quit smo-
keless tobacco because of its mechanism of action. It
can stimulate the release of sufficient dopamine to
reduce craving and withdrawal while simultaneously
acting as a partial antagonist, thereby blocking the
binding of nicotine to the receptors―and conse-
quently the reinforcing effects of nicotine intake
14
―and reducing the likelihood of a full relapse. Studies
comparing users of smokeless tobacco with smokers
haveshownthatthetwoformsoftobaccoconsumption
are associated with similar concentrations of nicotine
in the blood and similar or slightly higher concentra-
tions of cotinine in users of smokeless tobacco.
1516 We
evaluated the efficacy and safety of varenicline com-
pared with placebo for the cessation of use of smoke-
less tobacco.
METHODS
Study design
From August 2008 to July 2009, we recruited daily
users of smokeless tobacco into this double blind, pla-
cebo controlled, randomised, multicentre, parallel
groupclinicaltrialinNorway(sevensites:oneataspe-
cialist smoking cessation clinic; six in primary care)
andSweden(ninesites:oneataspecialistsmokingces-
sation clinic; five in primary care; three in secondary
care hospitals). Participants were recruited almost
exclusively through newspaper advertising. Our pri-
mary objective was to examine the efficacy of vareni-
cline 1 mg twice daily compared with placebo for
cessation of smokeless tobacco after 12 weeks of treat-
ment. Secondary objectives included evaluations of
efficacy for a further 14 weeks of follow-up after treat-
mentandsafetythroughthe treatmentperiodandfour
weeks after the last dose.
Participants
To be included, men and women aged ≥18 had to be
using smokeless tobacco containing nicotine (at least
eighttimesaday duringthe previousyearwithnoper-
iodofabstinenceinthethreemonthsbeforescreening)
but be motivated to stop use of all tobacco products.
They had to be preparedto adhere to the protocol and
provide informed consent. Women of childbearing
age were included if they were not pregnant or breast
feedingand hadagreedtopractiseeffective contracep-
tion for at least one month before and for the duration
of the trial.
Exclusioncriteriaincluded useofanyothernicotine
containingproductsotherthansmokelesstobaccodur-
ing the previous three months (participants’ exhaled
carbon monoxide had to be ≤10 ppm at screening);
useofvarenicline,bupropion,ornicotinereplacement
treatmentwithinthepreviousthreemonths;useofany
other investigational drug from 30 days before to
30 days after the study; history of drug or alcohol mis-
use within the past 12 months; or any serious psychia-
tric or medical condition (for example, depression) or
treatment with any drugs that might interfere with the
outcome of the trial or interpretation of safety or effi-
cacy evaluations.
Interventions
Eligible participants were randomised to one of two
parallel treatment arms in a 1:1 ratio (varenicline:pla-
cebo) by using a telephone interactive voice response
system (IVRS). Participant identification numbers
were allocated in the numerical order in which partici-
pants were accepted to the study. Study investigators
contacted the IVRS to obtain participants’ identifica-
tion numbers and double blinded randomised alloca-
tions. The dose of varenicline was titrated up during
the first week (0.5 mg once daily for three days, then
0.5 mg twice daily for four days), followed by 1 mg
twice daily through week 12. Participants randomised
to placebo followed the same dosing regimen with
matching placebo tablets. Participants were instructed
to take tablets orally with water. Compliance with
treatment was documented at all study visits and at
the end of treatment visit during week 12.
Participants were instructed to set a target quit date
during days 8 to 28 after initiation of treatment.
Because of the lack of guidelines for behavioural sup-
port or counsellingfor cessation of smokeless tobacco,
participants were offered brief behavioural support or
counselling at the discretion of the investigator and in
accordance with local standard practice. In most cases
participants were given simple advice and helpful tips,
together with discussion of any topics or concerns
raised by the participants. The potential health risks
of smokeless tobacco were discussed only in response
to a query from a participant.
Assessments
Baselineassessmentsoccurredduringthefirstvisitand
included assessment of demography, medical history,
concomitantuseofdrugs,physicalexamination,blood
pressure, heart rate, and body weight. The latter was
reassessed at weeks 12 and 26. We obtained each par-
ticipant’s history of smoking and use of smokeless
tobacco and used a modified Fagerström test for nico-
tine dependence (modified for use of smokeless
tobacco, see appendix 1 on bmj.com). Each question
hadanassociatedscore,andthetotalscoreachievedby
the participant determined their level of nicotine
dependency.
Use of smokeless tobacco was assessed weekly at
weeks9-12andagainatweek26withaselfcompletion
questionnaire, modified from one designed for and
implemented in previous varenicline studies to collect
information about nicotine use. Abstinence from
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salivary cotinine at baseline and reassessed weekly
from weeks 9-12 and at week 26. Participants whose
cotinine concentration was >15 ng/ml at any given
time point were classified as non-responders (using
smokelesstobaccooranotherformofnicotinecontain-
ing product) for the corresponding end point, even if
they reported abstinence from tobacco.
To assess safety and tolerability of varenicline in
smokeless tobacco users, investigators recorded all
adverse events, either observed or reported by partici-
pants,includingdetailsonseverity(mild,moderate,or
severe),aswellastheinvestigators’expertmedicalopi-
nions on the relation of the adverse events to the study
treatment. These adverse events were coded using the
Medical Dictionary for Regulatory Activities (Med-
DRA). Adverse events were recorded from the time
of the first dose of study treatment up to 28 days after
the last dose was taken. For all adverse events, the
investigators determined the outcome of the adverse
event and whether any specific adverse events met
the criteria for classification as a serious adverse
event. A serious adverse event was defined as any
adverse event that was life threatening; caused death;
resulted in new admission to hospital or prolonged an
existing stay; led to a persistent or severe disability or
incapacity; resulted in a congenital anomaly or birth
defect; or required medical or surgical intervention to
prevent one of these outcomes listed. Serious adverse
events could also include any adverse event that the
sponsor or investigators considered serious enough to
be classified as such. If any adverse events or their
sequelaepersisted,follow-upwasrequireduntilresolu-
tionorstabilisationoccurredatalevelacceptabletothe
investigator and sponsor.
Participants could withdraw from the study them-
selves or at the discretion of the investigators or
sponsor (for example, for safety, behavioural, or
administrative reasons). Whenever possible, every
effort was made to document participants’ outcomes
such as abstinence, reasons for withdrawal, and safety
status. If a participant withdrew from the trial and also
withdrew consent for disclosure of future information,
no further evaluations were performed, and no addi-
tional data were collected.
Outcome measures
The primary efficacy end point was the continuous
abstinence rate over the last four weeks of study treat-
ment (weeks 9-12), defined as proportion of partici-
pants who reported abstaining from smokeless
tobaccoduringtheindicatedperiodconfirmedbycoti-
ninemeasurementsduringclinicvisits.Secondaryend
points included long term continuous abstinence rate
(weeks9-26),sevendaypointprevalenceofabstinence
(defined as the proportion of participants who
abstained from smokeless tobacco for the seven days
before the end of treatment (week 12) and the end of
the study (week 26)), and the safety and tolerability of
varenicline versus placebo for 12 weeks of treatment.
Statistical analysis
Analysesincludedallparticipantswhotookatleastone
dose of study medication. Participants who discontin-
ued the study were classified as still using smokeless
tobacco for the remainder of the study. Efficacy end
points were analysed with logistic regression models
with terms for study centre and treatment group. Sig-
nificance tests for the treatment comparison (vareni-
cline v placebo) were performed at the two sided 0.05
level,andthe95%confidenceintervalsweretwosided.
The study was designed to have at least 90% power
todetectadifferencebetweenvareniclineandplacebo,
assuming a response rate for the four week continuous
abstinence rate of 0.35 and 0.20, respectively (relative
risk 1.75), with a two sided significance of 0.05.
We conducted exploratory analyses to assess
whether treatment effects varied according to baseline
salivarycotinineconcentrationandbaselinescoreona
modified Fagerström test. We used logistic regression
models to analyse the four week and long term contin-
uous abstinence rates with additional terms for base-
line salivary cotinine concentration or baseline
modified Fagerström test score and their interaction
with treatment. The cotinine scores were defined as
1=<361 ng/ml, 2=361-499 ng/ml, and 3=≥500 ng/ml
(the upper limit of quantification for salivary cotinine
concentrations was 500 ng/ml). Cotinine scores were
assigned because the upper level of quantification was
500ng/mlandalmost60%ofparticipantshadbaseline
cotinine values in excess of this. The scores were cho-
sen to represent a ratio of about 1:1:2 of participants
and were tested for simple linear relations to the out-
comes.PossiblescoresonthemodifiedFagerströmtest
ranged from 1 to 10 (observed scores ranged from 3 to
10). We determined Spearman’s non-parametric rank
Assigned to receive placebo (n=218) Assigned to receive varenicline (n=214)
Screened (n=447)
Randomised (n=432)
Received placebo (n=218)
Completed study (n=170, 78%)
Received varenicline (n=213)
(1 participant randomised to varenicline
but did not return to take study medication)
Discontinued study (n=48, 22%):
  Adverse events (n=9, 4%)
  Lack of efficacy (n=13, 6%)
  Refusal to participate (n=19, 9%)
  Lost to follow-up (n=6, 3%)
  Other (n=1, 1%)
Completed study (n=170, 80%)
Included in efficacy and safety analyses
(n=218, 100%)
Included in efficacy and safety analyses
(n=213, 100%)
Discontinued study (n=43, 20%):
  Adverse events (n=19, 9%)
  Lack of efficacy (n=3, 1%)
  Refusal to participate (n=12, 6%)
  Lost to follow-up (n=9, 4%)
Fig 1 | Flow of participants through study
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totalscoresversusthebaselinesalivarycotininescores.
RESULTS
Of 447 participants screened, 432 were randomised to
receive varenicline (n=214; one participant did not
take any varenicline) or placebo (n=218); 170 partici-
pants in each treatment group completed the study
(fig 1).
Baseline and demographic characteristics
Demographic characteristics were comparable
between treatment groups; more than 88% of partici-
pants were men, with an average age of 43.9, and
weighing on average over 86 kg (table 1). Participants
averaged over 20 years of use of smokeless tobacco,
and at baseline used it about 15-16 times a day. In
total, 58% of the varenicline group and 65% of the pla-
cebo group had attempted to quit previously, with
average longest periods of abstinence of 3.1 days (var-
enicline) and 5.5 days (placebo) in the year before the
study (table 1). Around 48% were former smokers.
Users of smokeless tobacco in both groups seemed
to have high levels of nicotine dependence, as indi-
catedbyhighbaselinesalivarycotinineconcentrations
(300-499ng/mlcotininein113/399(28%);≥500ng/ml
cotinine in 234/399 (59%); the upper limit of quantifi-
cation for salivary cotinine concentrations was
500 ng/ml, so we could not determine the maximum
level or the frequency distribution above 500 ng/ml);
the short time (≤30 minutes) to first use of smokeless
tobaccoafterwaking(171/213(80%)inthevarenicline
group and 173/218 (79%) in the placebo group); and
themean(SD)scoresontheFagerströmtestatbaseline
(7.5 (1.6) and 7.6 (1.7), respectively; table 1).
Efficacy
Primary efficacy end point
Thecontinuousabstinencerateatthe endoftreatment
(weeks9-12)wassignificantlyhigherinthevarenicline
groupthanintheplacebogroup(59%(125)v39%(85);
risk difference 20%; number needed to treat 5) (fig 2).
Secondary efficacy end points
Continuous abstinence rates were also significantly
higher in the long term (weeks 9-26) in the varenicline
group than in the placebo group (45% (95) v 34% (73);
risk difference 11%; number needed to treat 9) than in
the placebo group (fig 2).
When we compared former smokers with never
smokers in both treatment groups combined, continu-
ous abstinence rates at week 9-26 were significantly
higher for former smokers than for never smokers
(44% (94) v 34% (73); risk difference 10%; number
needed to treat 10; relative risk 1.18, 1.02 to 1.33,
P=0.031).
Among non-responders (participants who self
reported use of nicotine containing products or with
salivary cotinine concentrations >15 ng/ml, or both)
at weeks 9-12, seven participants (three in the vareni-
clinegroup(3%ofnon-responders)andfourinthepla-
cebo group (3% of non-responders)) started smoking
cigarettes, pipes, or cigars. Similarly, at weeks 9-26
there were 14 non-responders (seven (6%) and seven
(5%), respectively) who started smoking cigarettes,
pipes, or cigars.
Consistent with the higher continuous abstinence
rate with varenicline at the end of treatment, seven
Table 1 |Demographic characteristics of participants at baseline according to allocation to
varenicline or placebo for help in cessation of use of smokeless tobacco products
Varenicline (n=213) Placebo (n=218)
Physical characteristics
No (%) of men 189 (89) 196 (90)
Mean (SD) age (years) 43.9 (12.0) 43.9 (12.0)
Mean (SD) weight (kg) 86.0 (13.8) 86.3 (14.3)
No (%) white 211 (99) 217 (100)
History of use of smokeless tobacco
Age at first use (years):
Mean (SD) 22.9 (11.6) 21.7 (10.2)
Range 11-66 6-60
No of years of use:
Mean (SD) 20.3 (11.0) 21.7 (11.8)
Range 1-45 1-50
Portions used per day:
Mean (SD) 15.4 (5.8) 15.9 (7.7)
Range 8-40 8-80
Longest period of abstinence in past year (days):
Mean (SD) 3.1 (11.4) 5.5 (13.7)
Range 0-90 0-90
No of previous serious quit attempts:
Mean (SD) 1.72 (2.67) 2.16 (5.04)
Range 0-15 0-50
No (%) who had never previously attempted to quit 90 (42) 77 (35)
Mean (SD) modified Fagerström test score* 7.5 (1.6) 7.6 (1.7)
No (%) of former smokers 104 (48) 104 (49)
*Modified score 0-10 (maximum). Questionnaire has not been standardised; mean score for representative
population of users of smokeless tobacco is unknown.
Weeks 9-12 1.60 (1.32 to 1.87)
1.42 (1.08 to 1.79)
Relative risk (95% CI)
<0.001
0.012
P value
Weeks 9-26
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Varenicline (n=213) Placebo (n=218)
Fig 2 | Continuous abstinence rates with varenicline versus
placebo achieved at end of treatment. Continuous abstinence
rates analysed with logistic regression models with terms for
study centre and treatment group
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in the varenicline group than the placebo group (58%
(124) v 39% (85); risk difference 19%; number needed
totreat5)(fig3). Thoughweek26sevendaypointpre-
valence of abstinence was numerically larger with var-
enicline than with placebo (48% (102) v 40% (87); risk
difference 18%; number needed to treat13) (fig 3), this
difference was not significant.
There were no significant differences in treatment
effectacrosscentres,althoughtherewere16studycen-
tresandthenumberofparticipantsinsomecentreswas
low. There were no significant effects of treatment by
country.
We performed post hoc analyses for continuous
abstinence rates and seven day point rates of absti-
nencebecauseatbaselinemoreparticipantsinthevar-
enicline group had previously attempted to quit
smokeless tobacco than those in the placebo group
(42%v35%,respectively).Adjustmentforwhetherpar-
ticipants had previously attempted to quit smokeless
tobacco or not did not substantially alter the results
reported for the a priori analyses above or the conclu-
sions drawn from them. Varenicline was significantly
better than placebo with respect to continuous absti-
nence rates at weeks 9-12 (relative risk 1.58, 95% con-
fidence interval 1.31 to 1.85, P<0.001) and at weeks 9-
26 (1.41, 1.08 to 1.77, P=0.014), and the seven day
point abstinence rates at week 12 (1.57, 1.29 to 1.84,
P<0.001). Seven day point abstinence rates at week 26
were not significantly different (1.23, 0.96 to 1.52,
P=0.096).
As expected from the literature, the two strongest
predictors of nicotine dependence―cotinine scores
and Fagerström test scores
1718―were correlated at
baseline (r=0.22; P<0.001). When we examined the
continuous abstinence rates at weeks 12 and 26, how-
ever, we found that neither baseline cotinine nor base-
line Fagerström test scoreswere predictive of outcome
(see appendix 2 on bmj.com). In non-responders at
weeks 9-12, median salivary cotinine concentrations
at week 12 were lower in the varenicline group (114
ng/ml)thanintheplacebogroup(307ng/ml),suggest-
ing less nicotine use in the varenicline group, though
these differences were not significant (P=0.193)
because of large variability in cotinine concentrations.
Safety and tolerability
Table 2 shows the most commonly reported adverse
events (≥5% incidence in either group). Of these
adverse events, the incidence of nausea (35% v 6% in
placebo group), headache (10% v 9%), fatigue (10% v
7%), and sleep disorder (10% v 7%) was at least 10% in
the varenicline group. Concerning neuropsychiatric
adverse events, only sleep disorder (10% v 7%), abnor-
mal dreams (8% v 1%), and insomnia (6% v 3%) were
higher with varenicline than with placebo (table 2).
Overall, five participants reported six serious
adverse events (two participants had three serious
adverse events in the varenicline group; three partici-
pants had three serious adverse events in the placebo
group). In the placebo group, one participant devel-
oped colon cancer, one ruptured an Achilles tendon,
andoneexperiencedcardiacfailure.Noneofthesewas
thought to be related to treatment. In the varenicline
group, one participant experienced moderate
Weeks 9-12 1.56 (1.28 to 1.83)
1.24 (0.96 to 1.53)
Relative risk (95% CI)
<0.001
0.092
P value
Weeks 9-26
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Fig 3 | Seven day point prevalence of abstinence for varenicline
and placebo at end of treatment. Point prevalences of
abstinence analysed with logistic regression models with
terms for study centre and treatment group
Table 2 |Adverse events during treatment (all causes) and
discontinuation of treatment because of adverse events.
Figures are numbers (percentages) of participants
Adverse events
Varenicline
(n=213)
Placebo
(n=218)
Occurrence of any adverse event 168 (79) 126 (58)
Dose reductions or temporary
withdrawal
17 (8) 12 (6)
Permanent discontinuations 19 (9) 9 (4)
Occurrence of serious adverse
events
2 (1) 3 (1)
Most commonly reported adverse events (≥5% in either treatment
group):
Gastrointestinal disorders
Abdominal pain 11 (5) 5 (2)
Diarrhoea 10 (5) 11 (5)
Flatulence 18 (9) 7 (3)
Nausea 74 (35) 14 (6)
General disorders and administration site conditions:
Fatigue 22 (10) 15 (7)
Irritability 11 (5) 9 (4)
Infections and infestations
Nasopharyngitis 12 (6) 8 (4)
Nervous system disorders
Headache 22 (10) 20 (9)
Reported neuropsychiatric adverse events (all frequencies):
Sleep disorder 22 (10) 15 (7)
Abnormal dreams 17 (8) 3 (1)
Insomnia 13 (6) 6 (3)
Nightmare 4 (2) 3 (1)
Depressed mood 4 (2) 3 (1)
Restlessness 2 (1) 4 (2)
Depression 2 (1) 5 (2)
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the study drug and one experienced two serious
adverseeventsofalossofconsciousnessandaresultant
traffic incident. This latter participant was a man aged
56 with a two year history of hypertension who was
also taking candesartan and amlodipine. He took var-
enicline for 56 days, and he had stopped using smoke-
less tobacco. Varenicline treatment was discontinued
on day 56 because he was experiencing sleep disorder
(including insomnia and somnolence), and two days
later he experienced a short loss of consciousness
while driving, which resulted in a traffic incident. He
recovered the same day and underwent carotid Dop-
pler ultrasonography five days later, with normal
results.Theinvestigatorjudgedtheeventoflossofcon-
sciousnessasrelatedtostudymedicationandthetraffic
incident as related to the loss of consciousness. At the
time of the loss of consciousness, however, the plasma
concentration of varenicline would have been rela-
tively low because its half life is 24.8 hours.
19
There were few dose reductions and temporary dis-
continuations(8%invareniclinegroupv6%inplacebo
group) or permanent discontinuations (9% v 4%)
because of adverse events (table 2).
DISCUSSION
In people using smokeless tobacco products, vareni-
cline resulted in significantly higher rates of continuous
abstinenceinthelastfourweeksoftreatmentandaftera
further 14 weeks’ follow-up after treatment. The seven
day point prevalence of abstinence was significantly
higher in the varenicline group than the placebo
group, although by week 26 the difference between
thegroupswasnolongersignificant.Themostcommon
adverse event in the varenicline group was nausea,
which is consistent with the trials of varenicline for
smokingcessation.
20-24Neuropsychiatricadverseevents
occurredatthesamerateinbothtreatmentgroups,with
the exception of sleep disorder, abnormal dreams, and
insomnia, which are well known side effects associated
with varenicline, and are in accordance with a pooled
safety analysis of 10 varenicline trials for smoking
cessation.
25 There were few dose reductions or tempor-
ary or permanent discontinuations from study drugs,
suggesting acceptable tolerability.
Response rates in both groups were higher than
thoseseenpreviouslyincorrespondingstudiesofsmo-
keless tobacco and higherthan those observed in trials
of varenicline for smoking cessation.
2021 The high quit
rate in our placebo group could reflect a high motiva-
tion to quit among all participants, especially as we
offered limited behavioural support. Participants
were recruited almost exclusively through newspaper
advertising, and, as they volunteered for the study,
their motivation was high. Previous studies, however,
haveusedthesameadvertisementrecruitmentmethod
fortrialsofvareniclineforsmokingcessationbutfound
lower response rates with placebo.
2627 Indeed, full
recruitment of participants to our trial took only five
months, which was much faster than the anticipated
eightmonths,suggestingthatthereisanunmetclinical
need for cessation interventions among users of smo-
kelesstobacco. Inaddition,the participantsin thistrial
might have been less resistant to cessation than corre-
spondingpopulationsofsmokers,whohavelongbeen
under pressure to quit. For example, a lower propor-
tion of the population in our trial had previously
attempted to quit smokeless tobacco compared with
the history of previous attempts to quit smoking
amongthepopulationsofprevioustrialsofvarenicline
in the West.
202123
Alternatively, the motivation to quit could be lower
for smokelesstobacco than for smokingbecause of the
perception that smokeless tobacco is less harmful.
About half of the study population were former smo-
kersandtheirquitratesat26weekswereexceptionally
highat44%overall.Inourtrial,thesmallerdifferential
treatment effect compared with smoking cessation
trials could be because of the high placebo response
rate, which could suggest lower dependence on nico-
tine,despitetheobservedhighnicotinedependenceas
measuredbythemodifiedFagerströmtestandsalivary
cotinine concentrations.
The nicotine dependence in users of smokeless
tobacco might have different characteristics compared
with the nicotine dependence of smokers. For exam-
ple, in our trial, despite evidence of high nicotine
dependence in the study population, the success rates
in both groups―even in the placebo group―were
high.Itshouldalsobenotedthatsalivarycotininemea-
surement in smokeless tobacco users might not reflect
the same relation to nicotine metabolism in smokers
because some nicotine is swallowed, undergoes first
pass metabolism in the liver, and is immediately con-
verted to cotinine.
28 Furthermore, cotinine concentra-
tions and Fagerström test scores did not predict
outcome, which is contrary to findings in the smoking
cessation literature.
1718 Because the modified
Fagerström test we used is a novel assessment, how-
ever, there are no comparisons available in the litera-
ture at this time.
Strengths and limitations
As with all studies, there were some potential limita-
tions with this trial. Varenicline is currently not
licensed for smokeless tobacco cessation, and more
studies with longer follow-up might be needed to eval-
uate longer term efficacy. In future studies, the use of
moresupportintheformofbehaviouralinterventions,
for example, with dental examinations,
29 could be of
interest. The modified Fagerström test was developed
bytheoriginatorofthetestforsmokers(KFagerström)
buthasnotyetbeenvalidated,andfurtherstudieseval-
uating the utility of this test in measuring nicotine
dependence among smokeless tobacco users are war-
ranted. In addition, participants were almost exclu-
sively Norwegian or Swedish, most were men, and all
used a specific form of smokeless tobacco—namely,
snus—so the results might not generalise to other set-
tingsortousersofdifferenttypesofsmokelesstobacco
RESEARCH
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With regard to the form of smokeless tobacco, how-
ever, the primary addictive component of all products
is nicotine so the results would probably be replicated
inotherstudiesofotherforms.Also,theparticipantsof
this trial were all physically and psychologically
healthy.
Conclusions
Varenicline seems to be effective for smokeless
tobacco cessationand has an acceptablesafety and tol-
erability profile. As varenicline has proved significant
efficacy for smoking cessation, it is possible that it
might be suitable for treating nicotine dependence in
general, thus providing a useful new aid for the cessa-
tion of smokeless tobacco products. As the motivation
among users to quit was high in this study, it seems
likelythatthereisanurgentneedtoprovidemoresup-
port and encouragement to smokeless tobacco users
who would like to quit.
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